Emicizumab▼ HCP information

At Roche, we recognise and appreciate the interest that the haemophilia community has in regards to emicizumab, specifically around the subject of its long-term efficacy and safety, both now and in the future.

Emicizumab▼ HCP information

At Roche, we recognise and appreciate the interest that the haemophilia community has in regards to emicizumab, specifically around the subject of its long-term efficacy and safety, both now and in the future.

For that reason, we have collated published information on the benefit–risk profile of emicizumab, including long-term safety data, together with educational materials on post-marketing safety reporting and the pharmacovigilance process, which are available for all healthcare professionals to access on this website. We are also committed to ensuring that patient organisations for haemophilia and bleeding disorders continue to receive appropriate information regarding the safety and efficacy of emicizumab in a timely manner, so they may inform the patient communities that they serve.

Our promise and commitment to the haemophilia community remains unchanged and we will continue to listen, respond and partner with members of this community so that together we can make a collective effort for a continued dialogue to protect patient safety. We hope that you find the information on this website useful in informing your treatment decisions.

This website has been created to provide healthcare professionals with information regarding emicizumab from available clinical research data, real-world data and data from registries.

Note

▼ Emicizumab is subject to additional safety monitoring requirements. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to the regulatory authorities in your country according to your national requirements.